Serum Instittute

Schott Kaisha is a joint venture between specialty glass makers Schott AG from Germany and India's Kaisha, producing the highest number of ampoules and vials in the country at around 2.5 billion units per year.

US-based vaccine maker Novavax has filed regulatory submissions for emergency use authorization in India. The submissions were made to the Drugs Controller General of India (DCGI) through its partner, Serum Institute of India (SII), which also manufa

Serum Institute of India (SII) has written to Union Health Minister Mansukh Mandaviya suggesting reforms in the existing drug regulatory system, including allowing manufacturing and stockpiling of non-Covid vaccines while undergoing clinical trial.

World's biggest vaccine maker Serum Institute of India's Adar Poonawalla this morning urged the nations to "be patient" amid the wait for Covishield, the coronavirus vaccine that the SII has developed in partnership with the Oxford University and British-Swedish pharma firm AstraZeneca.

Schott Kaisha is a joint venture between specialty glass makers Schott AG from Germany and India's Kaisha, producing the highest number of ampoules and vials in the country at around 2.5 billion units per year.

US-based vaccine maker Novavax has filed regulatory submissions for emergency use authorization in India. The submissions were made to the Drugs Controller General of India (DCGI) through its partner, Serum Institute of India (SII), which also manufa

Serum Institute of India (SII) has written to Union Health Minister Mansukh Mandaviya suggesting reforms in the existing drug regulatory system, including allowing manufacturing and stockpiling of non-Covid vaccines while undergoing clinical trial.

World's biggest vaccine maker Serum Institute of India's Adar Poonawalla this morning urged the nations to "be patient" amid the wait for Covishield, the coronavirus vaccine that the SII has developed in partnership with the Oxford University and British-Swedish pharma firm AstraZeneca.